Ascendis Pharma (BMV:ASND N) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ASND N Aperçu des actions

A biopharmaceutical company, focuses on developing therapies for unmet medical needs.

ASND N analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	5/6
Performances passées	0/6
Santé financière	0/6
Dividendes	0/6

Récompenses

Se négocie à 77.3% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 66.89% par an

Analyse des risques

Capitaux propres négatifs

Les actions sont très illiquides

A moins d'un an de piste de trésorerie

Les actionnaires ont été dilués au cours de l'année écoulée

Ascendis Pharma A/S Concurrents

Telix Pharmaceuticals

ASX:TLX

AU$6.8b

Akeso

SEHK:9926

HK$58.4b

Arcellx

NasdaqGS:ACLX

US$4.4b

TG Therapeutics

NasdaqCM:TGTX

US$3.4b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Ascendis Pharma
Historique des cours de bourse
Prix actuel de l'action	US$2,090.00
Plus haut sur 52 semaines	US$2,115.00
Plus bas sur 52 semaines	US$2,090.00
Bêta	0.63
1Variation sur 1 mois	0%
Variation sur 3 mois	n/a
Variation sur 1 an	n/a
3Variation sur 3 ans	n/a
Variation sur 5 ans	-5.43%
Évolution depuis l'introduction en bourse	205.55%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	ASND N	MX Biotechs	MX Marché
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendement vs Industrie: Données insuffisantes pour déterminer la performance de ASND N par rapport au secteur MX Biotechs.

Rendement vs marché: Données insuffisantes pour déterminer la performance de ASND N par rapport au marché MX.

Volatilité des prix

Is ASND N's price volatile compared to industry and market?
ASND N volatility
ASND N Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Cours de l'action stable: ASND N n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de ASND N au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2006	879	Jan Mikkelsen	ascendispharma.com

Ascendis Pharma A/S Résumé des fondamentaux

Comment les bénéfices et les revenus de Ascendis Pharma se comparent-ils à sa capitalisation boursière ?
ASND N statistiques fondamentales
Capitalisation boursière	Mex$137.15b
Bénéfices(TTM)	-Mex$10.31b
Recettes(TTM)	Mex$6.77b

20.3x

Ratio P/S

-13.3x

Ratio P/E

Le site ASND N est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
ASND N compte de résultat (TTM)
Recettes	€329.02m
Coût des recettes	€47.34m
Marge brute	€281.68m
Autres dépenses	€783.25m
Les revenus	-€501.57m

Derniers bénéfices déclarés

Mar 31, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-8.75
Marge brute	85.61%
Marge bénéficiaire nette	-152.44%
Ratio dettes/capitaux propres	-239.8%

Quelles ont été les performances à long terme de ASND N?

Voir les performances historiques et les comparaisons

ASND N Aperçu des actions

Récompenses

Analyse des risques

Ascendis Pharma A/S Concurrents

ASX:TLX

AU$6.8b

SEHK:9926

HK$58.4b

NasdaqGS:ACLX

US$4.4b

NasdaqCM:TGTX

US$3.4b

Historique des prix et performances

Nouvelles et mises à jour récentes

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (Proc) Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024

Ascendis Pharma A/S to Report Q2, 2024 Results on Sep 03, 2024

Ascendis Pharma A/S Announces Food & Drug Administration Approves Yorvipath® (Palopegteriparatide; Developed as Transcon Pth) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Recent updates

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (Proc) Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024

Ascendis Pharma A/S to Report Q2, 2024 Results on Sep 03, 2024

Ascendis Pharma A/S Announces Food & Drug Administration Approves Yorvipath® (Palopegteriparatide; Developed as Transcon Pth) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Ascendis Pharma A/S Introduces Vision 2030

New minor risk - Profitability

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

New major risk - Negative shareholders equity

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Aendis Pharma A/S Reports One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

Ascendis Pharma Showcases its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

Ascendis Pharma A/S to Report Fiscal Year 2022 Results on Feb 16, 2023

Ascendis Pharma A/S Announces U.S. Food & Drug Administration Allows to Initiate an Expanded Access Program for Its Investigational Parathyroid Hormone Replacement Therapy, Transcon PTH

Ascendis Pharma Submits Marketing Authorization Application to the European Medicines Agency for Transcon™ PTH in Adult Patients with Hypoparathyroidism

TransCon CNP Achieves Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022

Third quarter 2022 earnings released: €3.03 loss per share (vs €1.47 loss in 3Q 2021)

Ascendis Pharma A/S Announces FDA Accepts for Priority Review Its NDA for TransCon(TM) PTH in Adult Patients with Hypoparathyroidism

Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for TranscendIT-101, A Phase 1/2 Clinical Trial of TransCon TLR7/8 Agonist in Solid Tumors

Ascendis Pharma A/S Appoints William Carl Fairey Jr. and Siham Imani as Class I Directors

Ascendis Pharma A/S announces new Week 110 data from the Phase 2 PaTH Forward Trial

Ascendis Pharma Submits Transcon™ Pth New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism

Second quarter 2022 earnings released: €1.46 loss per share (vs €2.50 loss in 2Q 2021)